Teveten HCT and Pregnancy
Because Teveten HCT (eprosartan/HCTZ) may harm a developing fetus, it is generally recommended that women not take this drug during pregnancy. Teveten HCT has been shown to cause skull deformities, kidney problems, and even death when used during the second or third trimester. Talk to your healthcare provider if you are thinking of becoming pregnant or become pregnant while taking this drug.
Can Pregnant Women Take Teveten HCT?Teveten® HCT (eprosartan/HCTZ) is a prescription medication used to lower blood pressure in people with hypertension (high blood pressure). It is a combination of two blood pressure medications. Teveten HCT is not recommended for use during pregnancy, as it can harm an unborn child.
What Are Pregnancy Categories C and D?Teveten HCT is classified as a pregnancy Category C medication when used in the first trimester and a pregnancy Category D medication when used during the second or third trimester.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been adequately studied in pregnant humans but did appear to cause harm to the fetus in animal studies.
In addition, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Pregnancy Category D is a classification given to medicines that have been shown to present a risk to the fetus in studies of pregnant women but may still offer benefits that outweigh the risks the drug presents. A pregnancy Category D medicine may still be given to a pregnant woman if the healthcare provider believes that the benefits to the woman outweigh the possible risks to her unborn child.